Doximity, Inc. · NYSE:DOCS

Doximity — Q2 FY2025 Earnings Presentation

20 slides from Doximity's earnings presentation, November 2024

  1. Slide 1: Investor Presentation Fall 2024

    Slide 1: Investor Presentation Fall 2024

    INVESTOR PRESENTATION Fall 2024

  2. Slide 2: Legal Disclaimer

    Slide 2: Legal Disclaimer

    LEGAL DISCLAIMER This presentation and associated commentary may contain forward-looking statements, including statements regarding expectations of future results of operations or financial performance of Doximity, market size and growth opportunities, the calculation of certain of our key financial

  3. Slide 3: The Digital Platform for Doctors

    Slide 3: The Digital Platform for Doctors

    THE DIGITAL PLATFORM FOR DOCTORS Leading Network Blue Chip Clients Growth and Profit 80%+ 20/20 Top Hospitals 17% of all U.S. and Health Systems Subscription Physicians1 Top Pharmaceutical Revenue Growth4 Manufacturers3 >600K 116% 53% Workflow Unique Net Revenue Adj. EBITDA Active Providers2 Retention

  4. Slide 4: Glaring Day-to-Day Inefficiencies

    Slide 4: Glaring Day-to-Day Inefficiencies

    GLARING DAY-TO-DAY INEFFICIENCIES 80% of US HC documents sent via snail mail and fax1 78% of physicians report burnout, with health IT as one of least satisfying factors2 1. Keeping it Together Issue Brief on Exchanging Medical Documentation CAQH Nov 2020. Does not include email. 2. 2018 Survey of A

  5. Slide 5: Bringing Tech to Medicine

    Slide 5: Bringing Tech to Medicine

    BRINGING TECH TO MEDICINE Inspired by enterprise tech Purpose-built for healthcare Networking Professional Network Professional Profiles, Search, Colleague Connectivity, Career Management News & Scheduling Newsfeed eSignatures Medical Articles & News, Peer Updates, Clinical Discussions, Sponsored Con

  6. Slide 6: Purpose Built for Healthcare

    Slide 6: Purpose Built for Healthcare

    PURPOSE BUILT FOR HEALTHCARE Professional Network Newsfeed Productivity Investor InvestorPresentation Presentation——November, November,2024 2024

  7. Slide 7: Engagement Throughout the Day

    Slide 7: Engagement Throughout the Day

    ENGAGEMENT THROUGHOUT THE DAY 1 Investor Presentation — November, 2024 1. Doximity usage by prescribers (MD/DO/NP/PA/CRNA/Pharmacist/Med Student) in fiscal quarter ending 3/31/24. For News, darker shades represent higher activity on Doximity's Newsfeed. For Workflow, darker shades represent higher act

  8. Slide 8: Our Commercial Solutions

    Slide 8: Our Commercial Solutions

    OUR COMMERCIAL SOLUTIONS Marketing Hiring Enterprise Workflow Educate on Latest News & Treatments Uncover Passive Candidates Reduce No-Shows & Leakage Relevance and personalization drive Rx’s & Referrals Find specialized talent #1 “Best in KLAS” Telehealth Video Conferencing Hundreds of thousands of

  9. Slide 9: Marketing Solutions

    Slide 9: Marketing Solutions

    MARKETING SOLUTIONS Largest Revenue Driver: Marketing Solutions Health Systems 2 17:1 ROI LexisNexis Pharma Leading Network Subscription Pricing Model >73% of healthcare spend 1. Audience (e.g. specialty) 3 is decided by Doctors1 2. Number of audience members > 11:1 ROI 3. Type and number of modules

  10. Slide 10: Land & Expand Sales Motion

    Slide 10: Land & Expand Sales Motion

    LAND & EXPAND SALES MOTION 1 Land Initial Brands or Service Lines 2 Expand to Add’l Brands or Service Lines Service Service Brand Line Line 07 07 08 Service Service Service Brand Brand Brand Line Line Line 04 05 06 04 05 06 Service Service Service Service Brand Brand Brand Brand Line Line Line Line

  11. Slide 11: Core Module Portfolio

    Slide 11: Core Module Portfolio

    CORE MODULE PORTFOLIO We create customized packages for customers Long Form Video Short Form Investor DOCSPresentation Investor Day——November, 2024 June 6, 2023

  12. Slide 12: Workflow Modules

    Slide 12: Workflow Modules

    WORKFLOW MODULES Point of Care Formulary Investor DOCSPresentation Investor Day——November, 2024 June 6, 2023

  13. Slide 13: Large & Growing Total Addressable Market

    Slide 13: Large & Growing Total Addressable Market

    LARGE & GROWING TOTAL ADDRESSABLE MARKET + + (1) (2) (3) 1. Pharmaceutical Marketing TAM represents total annual marketing spend by Pharmaceutical Manufacturers to Doctors. Source: IQVIA 2019 US ChannelDynamics and Kantar Media Intelligence, US Healthcare Ad Spend 2. Health System Marketing and Staf

  14. Slide 14: Rx Brand Opportunity

    Slide 14: Rx Brand Opportunity

    RX BRAND OPPORTUNITY Doximity Brand Penetration Doximity Brand Penetration Estimated Doximity Share of HCP $100M+ US Sales1 <$100M US Sales2 Marketing Budgets by Brand3 % of Brands in Each Cohort % of Brands in Each Cohort % of Brands in Each Cohort 4% 3% 1. As of March 31, 2024. # of brands with $1

  15. Slide 15: Q2 Key Metrics

    Slide 15: Q2 Key Metrics

    Q2 KEY METRICS LAND & EXPAND Number of Customers w/ $500K+ of Revenue1 Net Revenue Retention2 116% Total Company 103 $500K+ + 12% y/y Top 20 Customers 124% 1. Refer to appendix for the definition of customers with trailing 12-month subscription revenue greater than $500,000. 2. Refer to appendix for

  16. Slide 16: Attractive Revenue Growth & Margin Profile

    Slide 16: Attractive Revenue Growth & Margin Profile

    ATTRACTIVE REVENUE GROWTH & MARGIN PROFILE Revenue1 Adj. EBITDA & Margin1,2 51% 36% 74% CAGR CAGR 48% 44% 44% 31% 23% 11% 3 3 1. Fiscal Year ended March 31. 2. Refer to appendix for the definition and non-GAAP reconciliation of Adjusted EBITDA and Adjusted EBITDA margin. Investor Presentation — Novem

  17. Slide 17: Founder-Led, Mission Driven

    Slide 17: Founder-Led, Mission Driven

    FOUNDER-LED, MISSION DRIVEN 830 Jeff Tangney CEO & Co-Founder Dr. Nate Gross CSO & Co-Founder Anna Bryson CFO EMPLOYEES1 Lisa Greenbaum CCO Jey Balachandran CTO Amit Phull, MD Chief Physician Experience Officer 1/3+ IN R&D1 Ben Greenberg Joel Davis Jennifer Chaloemtiarana SVP Commercial Products SVP

  18. Slide 18: Company Highlights

    Slide 18: Company Highlights

    COMPANY HIGHLIGHTS 1 Leading digital platform for doctors 2 Powerful network effects 3 Sustainable revenue growth & profitability 4 Veteran vertical team 5 Massive near-term market opportunity fueled by shift to digital Investor Presentation — November, 2024

  19. Slide 19: Appendix: Non-GAAP Financial Measures

    Slide 19: Appendix: Non-GAAP Financial Measures

    APPENDIX: NON-GAAP FINANCIAL MEASURES To supplement our condensed consolidated financial statements, which are prepared and presented in accordance with accounting principles generally accepted in the United States ("GAAP"), the Company uses the following non-GAAP measures of financial performance:

  20. Slide 20: Appendix: Adjusted EBITDA & Margin Non-GAAP Reconciliation

    Slide 20: Appendix: Adjusted EBITDA & Margin Non-GAAP Reconciliation

    APPENDIX: ADJUSTED EBITDA & MARGIN NON-GAAP RECONCILIATION Year Ended March 31, TTM 2020 2021 2022 2023 2024 Q2 FY25 (in thousands) (in thousands) Net Income $29,737 $50,210 $154,783 $112,818 $147,582 $174,105 Adjustments: Acquisition and other related expenses 1,158 496 254 30 ‒ ‒ Stock-based compe

Source: Internet Archive copy of s201.q4cdn.com

More decks from Doximity, Inc.

All 21 Doximity decks